Symbols / EVGN Stock $0.81 +5.13% Evogene Ltd.

Healthcare • Biotechnology • Israel • NCM
EVGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Ofer Haviv CPA
Exch · Country NCM · Israel
Market Cap 9.81M
Enterprise Value 9.02M
Income -14.16M
Sales 3.85M
FCF (ttm) -17.49M
Book/sh -0.01
Cash/sh 1.31
Employees 52
Insider 10d —
IPO Oct 15, 2010
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.01
PEG —
P/S 2.55
P/B -90.10
P/C —
EV/EBITDA -0.68
EV/Sales 2.34
Quick Ratio 3.96
Current Ratio 4.54
Debt/Eq 18.36
LT Debt/Eq —
EPS (ttm) -1.70
EPS next Y -0.80
EPS Growth —
Revenue Growth -80.50%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-20
Earnings (prior) 2026-03-05
ROA -28.77%
ROE -100.69%
ROIC —
Gross Margin -6.25%
Oper. Margin -15.82%
Profit Margin -220.22%
Shs Outstand 12.10M
Shs Float 9.83M
Insider Own 0.96%
Instit Own 2.25%
Short Float 1.41%
Short Ratio 1.42
Short Interest 169.68K
52W High 2.42
vs 52W High -66.49%
52W Low 0.72
vs 52W Low 12.62%
Beta 0.95
Impl. Vol. —
Rel Volume 0.07
Avg Volume 487.69K
Volume 36.11K
Target (mean) $2.25
Tgt Median $2.25
Tgt Low $2.25
Tgt High $2.25
# Analysts 1
Recom Strong_buy
Prev Close $0.77
Price $0.81
Change 5.13%
About

Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.25
Mean price target
2. Current target
$0.81
Latest analyst target
3. DCF / Fair value
$-26.02
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.81
Low
$2.25
High
$2.25
Mean
$2.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-05-22 main Lake Street Buy → Buy $4
2024-08-23 main Lake Street Buy → Buy $12
2023-10-02 init Alliance Global Partners — → Buy $2
2023-08-18 main Lake Street Buy → Buy $3
2023-07-21 main Roth MKM Buy → Buy $6
2023-05-02 init Lake Street — → Buy $2
2022-09-12 main Aegis Capital — → Buy $8
2022-09-02 main Roth MKM Buy → Buy $3
2021-10-08 init Roth Capital — → Buy $7
2021-07-29 init Aegis Capital — → Buy $10
2020-12-01 init Cantor Fitzgerald — → Overweight $9
News
RSS: Latest EVGN news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
3.85
-30.91%
5.58
+87.02%
2.98
+78.03%
1.68
Operating Revenue
3.85
-30.91%
5.58
+87.02%
2.98
+78.03%
1.68
Cost Of Revenue
4.09
+72.02%
2.38
+59.73%
1.49
+63.92%
0.91
Reconciled Cost Of Revenue
4.09
+72.02%
2.38
+59.73%
1.49
+63.92%
0.91
Gross Profit
-0.24
-107.54%
3.20
+114.28%
1.49
+94.78%
0.77
Operating Expense
13.79
-37.31%
22.00
-7.26%
23.72
-14.38%
27.71
Research And Development
7.99
-36.10%
12.51
-22.75%
16.20
-22.10%
20.79
Selling General And Administration
5.76
-35.81%
8.98
+19.25%
7.53
-27.73%
10.41
Selling And Marketing Expense
0.18
-17.41%
0.22
+38.27%
0.16
+22.73%
0.13
General And Administrative Expense
5.58
-36.28%
8.75
+18.83%
7.37
-28.38%
10.28
Salaries And Wages
0.84
-43.16%
1.49
-2.37%
1.52
-74.64%
6.00
Other Gand A
4.73
-34.87%
7.27
+24.35%
5.84
+36.35%
4.29
Other Operating Expenses
0.04
-92.80%
0.51
—
-3.50
Total Expenses
17.89
-26.64%
24.38
-3.30%
25.21
-11.89%
28.62
Operating Income
-14.03
+25.37%
-18.80
+15.42%
-22.23
+17.48%
-26.94
Total Operating Income As Reported
-14.03
+25.37%
-18.80
+15.42%
-22.23
+17.48%
-26.94
EBITDA
-12.20
+8.73%
-13.36
+34.91%
-20.53
+23.98%
-27.01
Normalized EBITDA
-14.06
+17.93%
-17.13
+14.79%
-20.10
+17.73%
-24.43
Reconciled Depreciation
1.14
-17.16%
1.38
+6.23%
1.30
-49.61%
2.58
EBIT
-13.34
+9.52%
-14.74
+32.46%
-21.83
+26.22%
-29.59
Total Unusual Items
1.86
-50.58%
3.76
+975.35%
-0.43
+83.31%
-2.58
Total Unusual Items Excluding Goodwill
1.86
-50.58%
3.76
+975.35%
-0.43
+83.31%
-2.58
Net Income
-8.48
+48.53%
-16.48
+30.96%
-23.88
+10.36%
-26.64
Pretax Income
-13.50
+8.85%
-14.81
+32.53%
-21.95
+26.24%
-29.75
Net Non Operating Interest Income Expense
-1.28
-574.17%
0.27
-62.10%
0.71
+401.69%
-0.24
Interest Expense Non Operating
0.16
+149.21%
0.06
-44.74%
0.11
-30.91%
0.17
Net Interest Income
-1.28
-574.17%
0.27
-62.10%
0.71
+401.69%
-0.24
Interest Expense
0.16
+149.21%
0.06
-44.74%
0.11
-30.91%
0.17
Interest Income Non Operating
0.36
-56.32%
0.81
-16.67%
0.98
+437.36%
0.18
Interest Income
0.36
-56.32%
0.81
-16.67%
0.98
+437.36%
0.18
Other Income Expense
1.82
-51.11%
3.73
+966.28%
-0.43
+83.31%
-2.58
Gain On Sale Of Security
1.86
-50.58%
3.76
+975.35%
-0.43
+83.31%
-2.58
Tax Provision
0.00
-88.89%
0.01
-52.63%
0.02
-78.89%
0.09
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.43
-50.58%
0.87
+975.35%
-0.10
+83.31%
-0.59
Net Income Including Noncontrolling Interests
-7.83
+56.65%
-18.05
+30.44%
-25.95
+13.03%
-29.84
Net Income From Continuing Operation Net Minority Interest
-14.16
-6.86%
-13.25
+33.39%
-19.89
+25.33%
-26.64
Net Income From Continuing And Discontinued Operation
-8.48
+48.53%
-16.48
+30.96%
-23.88
+10.36%
-26.64
Net Income Continuous Operations
-13.50
+8.90%
-14.82
+32.54%
-21.96
+26.40%
-29.84
Net Income Discontinuous Operations
5.67
+275.22%
-3.24
+18.85%
-3.99
—
Minority Interests
-0.66
-141.94%
1.57
-24.39%
2.08
-35.28%
3.21
Normalized Income
-15.59
+3.45%
-16.15
+17.45%
-19.56
+20.67%
-24.65
Net Income Common Stockholders
-8.48
+48.53%
-16.48
+30.96%
-23.88
+10.36%
-26.64
Diluted EPS
-1.08
+62.63%
-2.89
+44.42%
-5.20
+20.00%
-6.50
Basic EPS
-1.08
+62.63%
-2.89
+44.42%
-5.20
+20.00%
-6.50
Basic Average Shares
7.87
+38.21%
5.70
+24.71%
4.57
+10.86%
4.12
Diluted Average Shares
7.87
+38.21%
5.70
+24.71%
4.57
+10.86%
4.12
Diluted NI Availto Com Stockholders
-8.48
+48.53%
-16.48
+30.96%
-23.88
+10.36%
-26.64
Earnings From Equity Interest
-0.04
+0.00%
-0.04
0.00
0.00
Total Other Finance Cost
1.48
+208.52%
0.48
+222.82%
0.15
-41.34%
0.25
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
20.05
-49.71%
39.86
-21.99%
51.10
-8.95%
56.13
Current Assets
15.63
-27.60%
21.59
-37.37%
34.47
-8.69%
37.75
Cash Cash Equivalents And Short Term Investments
12.96
-15.33%
15.30
-50.74%
31.06
-12.14%
35.35
Cash And Cash Equivalents
12.96
-15.33%
15.30
-26.34%
20.77
-28.32%
28.98
Cash Financial
12.96
-15.33%
15.30
-26.34%
20.77
-28.32%
28.98
Other Short Term Investments
—
0.01
-99.90%
10.29
+61.43%
6.38
Receivables
1.38
-7.33%
1.49
+84.95%
0.80
+0.12%
0.80
Accounts Receivable
0.32
-70.94%
1.09
+205.60%
0.36
+2.59%
0.35
Other Receivables
1.06
+167.93%
0.40
-11.41%
0.45
-1.76%
0.46
Accrued Interest Receivable
—
—
1.62
0.00
Inventory
0.21
-88.46%
1.82
+2293.42%
0.08
-86.57%
0.57
Prepaid Assets
0.50
-69.78%
1.67
-33.97%
2.53
+153.87%
0.99
Current Deferred Assets
0.55
-57.75%
1.30
0.00
—
Restricted Cash
0.03
+220.00%
0.01
0.00
-100.00%
0.03
Total Non Current Assets
4.42
-75.84%
18.27
+9.88%
16.63
-9.49%
18.38
Net PPE
2.64
-37.99%
4.25
+23.76%
3.44
-15.54%
4.07
Gross PPE
23.20
-7.94%
25.20
-3.06%
26.00
+3.65%
25.08
Accumulated Depreciation
-20.57
+1.85%
-20.95
+7.14%
-22.56
-7.36%
-21.02
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
3.34
-6.71%
3.58
+4.65%
3.42
+12.47%
3.04
Other Properties
3.83
-29.40%
5.43
+8.77%
4.99
+7.28%
4.66
Leases
16.03
-1.02%
16.19
-7.92%
17.59
+1.13%
17.39
Goodwill And Other Intangible Assets
0.00
-100.00%
12.20
-7.40%
13.17
-6.87%
14.14
Other Intangible Assets
—
12.20
-7.40%
13.17
-6.87%
14.14
Investments And Advances
0.04
-47.56%
0.08
0.00
—
Long Term Equity Investment
0.04
-47.56%
0.08
0.00
—
Non Current Accounts Receivable
—
—
—
0.07
Non Current Deferred Assets
1.17
-32.85%
1.74
0.00
-100.00%
0.09
Non Current Deferred Taxes Assets
—
1.74
0.00
-100.00%
0.09
Non Current Prepaid Assets
0.57
+4658.33%
0.01
-57.14%
0.03
-62.16%
0.07
Total Liabilities Net Minority Interest
8.07
-67.75%
25.03
+11.64%
22.42
+5.06%
21.34
Current Liabilities
3.44
-81.58%
18.70
+169.23%
6.94
+23.45%
5.62
Payables And Accrued Expenses
1.95
-53.33%
4.18
-21.81%
5.34
+15.11%
4.64
Payables
1.09
-52.84%
2.31
-17.72%
2.80
+5.69%
2.65
Accounts Payable
0.64
-47.96%
1.23
-31.20%
1.78
+72.30%
1.04
Other Payable
0.45
-58.39%
1.08
+5.89%
1.02
-36.98%
1.62
Current Accrued Expenses
0.86
-53.93%
1.87
-26.33%
2.54
+27.68%
1.99
Pensionand Other Post Retirement Benefit Plans Current
—
—
2.54
+27.68%
1.99
Current Debt And Capital Lease Obligation
0.72
-93.47%
10.96
+1184.88%
0.85
-3.51%
0.88
Current Debt
—
10.37
—
—
Other Current Borrowings
—
10.37
—
—
Current Capital Lease Obligation
0.72
+21.56%
0.59
-30.95%
0.85
-3.51%
0.88
Current Deferred Liabilities
0.07
-89.31%
0.68
-8.93%
0.75
+642.57%
0.10
Current Deferred Revenue
0.07
-89.31%
0.68
-8.93%
0.75
+642.57%
0.10
Other Current Liabilities
0.71
-75.45%
2.88
—
—
Total Non Current Liabilities Net Minority Interest
4.63
-26.92%
6.33
-59.08%
15.47
-1.52%
15.71
Long Term Debt And Capital Lease Obligation
1.48
-22.57%
1.91
-82.03%
10.65
-3.56%
11.05
Long Term Debt
—
—
10.37
+2.51%
10.11
Long Term Capital Lease Obligation
1.48
-22.57%
1.91
+571.58%
0.28
-69.42%
0.93
Non Current Deferred Liabilities
3.15
-28.80%
4.42
-8.34%
4.82
+3.30%
4.67
Non Current Deferred Revenue
3.07
-28.98%
4.33
-2.24%
4.43
-5.12%
4.67
Stockholders Equity
-0.08
+94.35%
-1.45
-112.04%
12.05
-56.85%
27.93
Common Stock Equity
-0.08
+94.35%
-1.45
-112.04%
12.05
-56.85%
27.93
Capital Stock
0.49
+34.44%
0.36
+26.92%
0.29
+21.70%
0.23
Common Stock
0.49
+34.44%
0.36
+26.92%
0.29
+21.70%
0.23
Share Issued
8.72
+33.83%
6.51
+28.79%
5.06
+22.60%
4.13
Ordinary Shares Number
8.72
+33.83%
6.51
+28.79%
5.06
+22.60%
4.13
Additional Paid In Capital
281.99
+3.57%
272.26
+1.08%
269.35
+3.04%
261.40
Retained Earnings
-282.56
-3.10%
-274.07
-6.40%
-257.59
-10.22%
-233.71
Minority Interest
12.06
-25.98%
16.29
-2.06%
16.63
+142.45%
6.86
Total Equity Gross Minority Interest
11.97
-19.30%
14.84
-48.27%
28.68
-17.55%
34.79
Total Capitalization
-0.08
+94.35%
-1.45
-106.47%
22.42
-41.07%
38.04
Working Capital
12.19
+321.11%
2.89
-89.49%
27.52
-14.32%
32.13
Invested Capital
-0.08
-100.92%
8.92
-60.22%
22.42
-41.07%
38.04
Total Debt
2.20
-82.93%
12.87
+11.89%
11.51
-3.55%
11.93
Capital Lease Obligations
2.20
-12.19%
2.50
+119.95%
1.14
-37.33%
1.82
Net Tangible Assets
-0.08
+99.40%
-13.65
-1122.76%
-1.12
-108.09%
13.79
Tangible Book Value
-0.08
+99.40%
-13.65
-1122.76%
-1.12
-108.09%
13.79
Investmentsin Associatesat Cost
—
0.08
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.50
+31.46%
-19.70
+8.70%
-21.58
+8.87%
-23.68
Cash Flow From Continuing Operating Activities
-11.39
+35.00%
-17.52
+10.38%
-19.55
+17.44%
-23.68
Cash From Discontinued Operating Activities
-2.12
+3.03%
-2.18
-7.49%
-2.03
—
Net Income From Continuing Operations
-13.50
+8.90%
-14.82
+32.54%
-21.96
+26.40%
-29.84
Depreciation Amortization Depletion
1.14
-17.16%
1.38
+6.23%
1.30
-49.61%
2.58
Depreciation
1.14
-17.16%
1.38
+6.23%
1.30
-14.08%
1.51
Amortization Cash Flow
—
0.97
+0.31%
0.97
-9.00%
1.07
Depreciation And Amortization
1.14
-17.16%
1.38
+6.23%
1.30
-49.61%
2.58
Amortization Of Intangibles
—
0.97
+0.31%
0.97
-9.00%
1.07
Other Non Cash Items
-0.36
+53.26%
-0.77
-88.70%
-0.41
-113.13%
3.10
Stock Based Compensation
0.65
-47.39%
1.24
+12.18%
1.11
-6.58%
1.19
Asset Impairment Charge
2.43
0.00
0.00
—
Deferred Tax
-0.01
-166.67%
0.01
+127.27%
-0.03
-136.67%
0.09
Deferred Income Tax
-0.01
-166.67%
0.01
+127.27%
-0.03
-136.67%
0.09
Operating Gains Losses
-0.63
+77.65%
-2.81
-10707.69%
-0.03
—
Gain Loss On Investment Securities
-0.46
+86.43%
-3.37
—
—
Gain Loss On Sale Of PPE
-0.21
-139.81%
0.53
+2119.23%
-0.03
0.00
Change In Working Capital
-1.25
+52.05%
-2.61
-839.93%
-0.28
+63.94%
-0.77
Change In Receivables
1.71
+856.42%
0.18
+114.29%
-1.25
-219.79%
1.05
Changes In Account Receivables
0.67
+206.06%
-0.63
-8857.14%
-0.01
+89.55%
-0.07
Change In Inventory
-1.02
+20.20%
-1.28
-361.15%
0.49
+203.16%
-0.47
Change In Prepaid Assets
—
—
—
—
Change In Payables And Accrued Expense
-1.58
-65.79%
-0.96
-223.51%
0.77
+170.62%
-1.10
Change In Accrued Expense
-0.76
-37.96%
-0.55
-203.01%
0.53
+178.81%
-0.68
Change In Payable
-0.83
-103.19%
-0.41
-268.60%
0.24
+157.48%
-0.42
Change In Account Payable
-0.26
+58.89%
-0.63
-183.22%
0.76
+261.41%
-0.47
Change In Other Working Capital
-0.36
+35.42%
-0.56
-94.10%
-0.29
-16.60%
-0.25
Investing Cash Flow
17.74
+84.35%
9.62
+312.03%
-4.54
-134.19%
13.27
Cash Flow From Continuing Investing Activities
-0.01
-100.06%
9.57
+321.11%
-4.33
-132.62%
13.27
Cash From Discontinued Investing Activities
17.74
+36866.67%
0.05
+123.08%
-0.21
—
Net PPE Purchase And Sale
-0.06
+90.75%
-0.62
-11.80%
-0.55
+52.95%
-1.17
Purchase Of PPE
-0.14
+78.43%
-0.63
-8.49%
-0.58
+50.73%
-1.17
Sale Of PPE
0.08
+680.00%
0.01
-61.54%
0.03
0.00
Capital Expenditure
-0.14
+78.43%
-0.63
-8.49%
-0.58
+50.73%
-1.17
Net Investment Purchase And Sale
-0.00
-100.01%
10.19
+369.65%
-3.78
-126.16%
14.45
Purchase Of Investment
-0.00
+99.99%
-17.15
+12.96%
-19.70
-2062.79%
-0.91
Sale Of Investment
0.00
-100.00%
27.34
+71.69%
15.92
+3.70%
15.36
Net Other Investing Changes
0.05
—
—
—
Financing Cash Flow
-6.60
-241.80%
4.66
-74.35%
18.15
+94.28%
9.34
Cash Flow From Continuing Financing Activities
-6.49
-241.85%
4.57
-74.97%
18.27
+95.54%
9.34
Net Issuance Payments Of Debt
-0.53
+40.63%
-0.89
-31.26%
-0.68
+15.94%
-0.80
Issuance Of Debt
—
—
0.00
-100.00%
10.00
Repayment Of Debt
-0.53
+40.63%
-0.89
-31.26%
-0.68
+15.94%
-0.80
Long Term Debt Issuance
—
—
0.00
-100.00%
10.00
Long Term Debt Payments
-0.53
+40.63%
-0.89
-31.26%
-0.68
+15.94%
-0.80
Net Long Term Debt Issuance
-0.53
+40.63%
-0.89
-31.26%
-0.68
+15.94%
-0.80
Net Common Stock Issuance
4.28
-23.83%
5.62
-33.45%
8.45
+40133.33%
0.02
Proceeds From Stock Option Exercised
—
5.50
0.00
-100.00%
0.01
Net Other Financing Charges
-10.24
-6146.34%
-0.16
-101.56%
10.49
+3.73%
10.12
Changes In Cash
-2.37
+56.36%
-5.42
+31.91%
-7.96
-650.52%
-1.06
Effect Of Exchange Rate Changes
0.02
+142.86%
-0.05
+80.00%
-0.24
+89.27%
-2.28
Beginning Cash Position
15.30
-26.34%
20.77
-28.32%
28.98
-10.35%
32.33
End Cash Position
12.96
-15.33%
15.30
-26.34%
20.77
-28.32%
28.98
Free Cash Flow
-13.64
+32.91%
-20.33
+8.25%
-22.15
+10.85%
-24.85
Common Stock Issuance
4.28
-23.83%
5.62
-33.45%
8.45
+40133.33%
0.02
Earnings Losses From Equity Investments
0.04
+0.00%
0.04
0.00
0.00
Interest Paid CFO
-0.19
-188.06%
-0.07
+44.63%
-0.12
+26.67%
-0.17
Interest Received CFO
0.34
-63.81%
0.93
+3.20%
0.91
+386.56%
0.19
Issuance Of Capital Stock
4.28
-23.83%
5.62
-33.45%
8.45
+40133.33%
0.02
Taxes Refund Paid
-0.01
+0.00%
-0.01
+64.52%
-0.03
+22.50%
-0.04
Cash From Discontinued Financing Activities
-0.12
-238.55%
0.08
+170.94%
-0.12
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category